Truist Financial’s Axsome Therapeutics AXSM Stock Holding History

Truist Financial’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$471K	Sell	2,789 -266	-9%	-$45.9K	﹤0.01%	2115
2025 Q4	$558K	Buy	3,055 +1,100	+56%	+$154K	﹤0.01%	1987
2025 Q3	$237K	Buy	+1,955	New	+$220K	﹤0.01%	2455
2025 Q2	–	Sell	-2,048	Closed	-$239K	–	2599
2025 Q1	$239K	Buy	+2,048	New	+$233K	﹤0.01%	2270
2024 Q4	–	Sell	-21,083	Closed	-$1.89M	–	2520
2024 Q3	$1.89M	Hold	21,083	–	–	﹤0.01%	1256
2024 Q2	$1.7M	Hold	21,083	–	–	﹤0.01%	1349
2024 Q1	$1.68M	Sell	21,083 -3	-0%	-$252	﹤0.01%	1362
2023 Q4	$1.68M	Buy	+21,086	New	+$1.41M	﹤0.01%	1357

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Truist Financial's AXSM Position: Q1 2026 in Review

Truist Financial reduced its Axsome Therapeutics (AXSM) stake by 8.7% in Q1 2026, selling an estimated $45.9K and leaving 2,789 shares worth $471K. The position accounts for ﹤0.01% of the portfolio, ranked #2115.

Truist Financial first reported a position in AXSM in Q4 2023 and has held it in 8 quarters since. The position peaked at $1.89M in Q3 2024. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Truist Financial held 2,789 shares of Axsome Therapeutics worth $471K as of Q1 2026.
Truist Financial sold 266 Axsome Therapeutics shares in Q1 2026, an estimated $45.9K.
Axsome Therapeutics made up ﹤0.01% of Truist Financial's portfolio in Q1 2026, its #2115 holding.
Truist Financial first reported a position in Axsome Therapeutics in Q4 2023 and has held it in 8 quarters since.
Truist Financial's Axsome Therapeutics position peaked at $1.89M in Q3 2024.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Truist Financial's 13F filing for Q1 2026, filed 27 Apr 2026.